tiprankstipranks
Advertisement
Advertisement
Viridian Therapeutics sees cash runway through profitability
PremiumThe FlyViridian Therapeutics sees cash runway through profitability
20d ago
“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
Premium
Market News
“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
1M ago
Viridian Therapeutics price target raised to $43 from $32 at Wedbush
Premium
The Fly
Viridian Therapeutics price target raised to $43 from $32 at Wedbush
2M ago
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
PremiumThe FlyWells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
2M ago
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Premium
The Fly
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
2M ago
Analyst Initiates Buy on Viridian, Citing Competitive Lumvoa Launch and Pipeline-Driven Long-Term Growth
Premium
Ratings
Analyst Initiates Buy on Viridian, Citing Competitive Lumvoa Launch and Pipeline-Driven Long-Term Growth
2M ago
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing
PremiumCompany AnnouncementsViridian Therapeutics secures WuXi deal for veligrotug manufacturing
3M ago
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
Premium
The Fly
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
3M ago
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
Premium
The Fly
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100